Cargando…

Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients

The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorente, Leonardo, Martín, María M., Pérez-Cejas, Antonia, Barrios, Ysamar, Solé-Violán, Jordi, Ferreres, José, Labarta, Lorenzo, Díaz, César, Jiménez, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133861/
https://www.ncbi.nlm.nih.gov/pubmed/27834822
http://dx.doi.org/10.3390/ijms17111861
_version_ 1782471355167408128
author Lorente, Leonardo
Martín, María M.
Pérez-Cejas, Antonia
Barrios, Ysamar
Solé-Violán, Jordi
Ferreres, José
Labarta, Lorenzo
Díaz, César
Jiménez, Alejandro
author_facet Lorente, Leonardo
Martín, María M.
Pérez-Cejas, Antonia
Barrios, Ysamar
Solé-Violán, Jordi
Ferreres, José
Labarta, Lorenzo
Díaz, César
Jiménez, Alejandro
author_sort Lorente, Leonardo
collection PubMed
description The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074−1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days.
format Online
Article
Text
id pubmed-5133861
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-51338612016-12-12 Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients Lorente, Leonardo Martín, María M. Pérez-Cejas, Antonia Barrios, Ysamar Solé-Violán, Jordi Ferreres, José Labarta, Lorenzo Díaz, César Jiménez, Alejandro Int J Mol Sci Article The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074−1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days. MDPI 2016-11-08 /pmc/articles/PMC5133861/ /pubmed/27834822 http://dx.doi.org/10.3390/ijms17111861 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lorente, Leonardo
Martín, María M.
Pérez-Cejas, Antonia
Barrios, Ysamar
Solé-Violán, Jordi
Ferreres, José
Labarta, Lorenzo
Díaz, César
Jiménez, Alejandro
Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
title Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
title_full Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
title_fullStr Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
title_full_unstemmed Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
title_short Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
title_sort association between interleukin-6 promoter polymorphism (-174 g/c), serum interleukin-6 levels and mortality in severe septic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133861/
https://www.ncbi.nlm.nih.gov/pubmed/27834822
http://dx.doi.org/10.3390/ijms17111861
work_keys_str_mv AT lorenteleonardo associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT martinmariam associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT perezcejasantonia associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT barriosysamar associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT soleviolanjordi associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT ferreresjose associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT labartalorenzo associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT diazcesar associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients
AT jimenezalejandro associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients